Prevest Denpro (543363)

FairStock Score: 46/100 — MIXED

Score breakdown: P/E: 1/3 · ROCE: 2/2 · Growth: 2/2 · Dividend: 0/1

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I'm looking at Prevest Denpro, a ₹749 Cr medical equipment and supplies company trading at ₹616.50, right at its 52-week high. Mr. Market is paying roughly 26 times earnings and a PEG of 1.37. For a business that has compounded revenue at 20.79% over five years and grew sales 23.04% recently, that is not outrageous, but it is not a bargain either. Graham would demand a margin of safety; Buffett would ask about durability. The numbers show decent quality: ROCE of 25.25% suggests capital efficiency, and a Piotroski F-Score of 7/9 indicates improving fundamentals. The latest quarter had ₹18 Cr sales and ₹5 Cr net profit, roughly a 28% net margin, which is attractive. Yet profit growth of 15.47% trails sales growth, so I must watch whether margins are peaking or costs are rising. Debt/equity, ROE, book value and promoter holding are not available here, and without them I cannot fully judge financial strength or management alignment. Dividend yield is only 0.22%, so almost all return must come from growth. FairStock Score 46/100 says mixed. The company may be a fast grower, but at the top of its 52-week range and with incomplete data, I would wait for a wider discount or clearer evidence of a moat. No durable competitive advantage is proven by these figures alone. For an Indian retail investor, this is a watchlist candidate, not a fat pitch.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer